New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GSK;ABC;CAH;MCK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
March 2, 2015
12:13 EDTCAHOn The Fly: Midday Wrap
Subscribe for More Information
11:52 EDTCAHJohnson & Johnson EPS dilution from Cordis deal seems modest, says Wells Fargo
Wells Fargo estimates that Johnson & Johnson's (JNJ) planned sale of Cordis to Cardinal Health (CAH) should dilute J&J yearly EPS by about 3c-4c, assuming all is else equal, and the firm expects the company to be able to absorb at least some of this dilution and possibly offset the rest via share repurchases. Wells maintains its Outperform rating on J&J shares.
08:12 EDTCAHPharMerica announces wholesale agreement with Cardinal Health
PharMerica Corporation (PMC) announced that it has entered into a new wholesale drug distribution agreement with Cardinal Health (CAH). The new agreement will take effect on April 1 and extend through June 2018. As part of the agreement, Cardinal Health will assume responsibility for the sourcing and distribution of branded and generic pharmaceuticals for PharMerica.
08:01 EDTCAHCardinal Health offers to buy Cordis from Johnson & Johnson in $1.99B deal
Subscribe for More Information
07:53 EDTCAHCardinal Health to host conference call
Subscribe for More Information
07:35 EDTCAHCardinal Health to buy Cordis from Johnson & Johnson in $1.99B deal
Subscribe for More Information
07:35 EDTCAHCardinal Health to acquire Cordis for $1.94B in cash
Cardinal Health (CAH) announced plans to acquire Johnson & Johnson's (JNJ) Cordis business, a global manufacturer of cardiology and endovascular devices, for $1.94B in cash, or approximately $1.59B, net of the present value of tax benefits. The acquisition is expected to be financed with a combination of $1B in new senior unsecured notes and the remainder with existing cash. The transaction is expected to close in the United States and key non-U.S. countries towards the end of calendar 2015. Assuming this timing, Cardinal Health expects fiscal 2017 accretion in non-GAAP diluted earnings per share from continuing operations of greater than 20c per share, which includes the cost of an incremental 7c-8c per share of interest expense associated with financing the transaction. The company expects the acquisition to be increasingly accretive thereafter and assumes that synergies will exceed $100M annually by the end of fiscal 2018. Cordis had annual sales in 2014 of approximately $780M, split almost evenly between cardiology and endovascular products. Upon completion of that process, Cardinal Health expects to enter into a definitive purchase and sale agreement in respect of the proposed acquisition. The proposed transaction will also be subject to customary closing conditions, including regulatory approvals, and is expected to close in the approximately 20 principal countries towards the end of calendar year 2015 and in the remaining countries on a rolling basis afterward.
07:04 EDTGSKIsis Pharmaceuticals earns $15M from GlaxoSmithKline for advancing ISIS-TTR Rx
Isis Pharmaceuticals (ISIS) announced that it has earned a $15M milestone payment from GSK (GSK) related to advancing the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug Isis is developing with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $60 million in upfront and milestone payments for advancing ISIS-TTRRx. In addition, if GSK elects to exercise its option to exclusively license ISIS-TTRRx, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
February 26, 2015
14:03 EDTABCGabelli liquidates 7.69% stake in MWI Veterinary Supply
As a result of the completion of the acquisition of the company by the AmerisourceBergen (ABC), Gabelli no longer has beneficial ownership of any of the company's shares.
11:50 EDTCAHCardinal Health management to meet with William Blair
Subscribe for More Information
February 25, 2015
12:13 EDTGSKGlaxoSmithKline sees Novartis transaction closing next week
Subscribe for More Information
11:24 EDTGSKGlaxoSmithKline announces return of alli to retail stores
Subscribe for More Information
February 24, 2015
15:18 EDTABCAmerisourceBergen completes acquisition of MWI Veterinary Supply
AmerisourceBergen (ABC) announced the completion of its acquisition of MWI Veterinary Supply (MWIV). At the effective time of the merger, all remaining shares of MWI common stock not tendered into the tender offer were converted into the right to receive $190 in cash, without interest and less any applicable withholding taxes, which is the same price that was paid in the tender offer. As a result of the transaction, MWI has become a wholly owned subsidiary of AmerisourceBergen.
07:36 EDTABCAmerisourceBergen completes tender offer for MWI Veterinary Supply shares
AmerisourceBergen Corporation (ABC) has successfully completed its tender offer to purchase all outstanding shares of MWI Veterinary Supply (MWIV) common stock for $190.00 per share in cash, without interest and less any applicable withholding taxes. The tender offer expired at 11:59 p.m., New York City time, on February 23. As of the expiration of the tender offer, 10,096,484 shares had been validly tendered and not validly withdrawn, representing approximately 78.1% of MWI's outstanding shares of common stock on a fully diluted basis. All conditions to the tender offer have been satisfied, and AmerisourceBergen has accepted for payment and will promptly pay the depositary for all validly tendered shares. AmerisourceBergen expects to complete the acquisition of MWI later today through a merger without a vote or meeting of MWI's stockholders.
07:31 EDTCAHRBC Capital to hold a conference
Subscribe for More Information
February 23, 2015
13:33 EDTGSKRBS could name Howard Davies as chairman this week, FT reports
Royal Bank of Scotland (RBS) could name Howard Davies as its chairman as early as Thursday, when the bank reports its full-year results, the Financial Times reports. Davies is currently chairman of insurance business Phoenix Group and chairs Morgan Stanley's (MS) risk committee. Current RBS Chairman Philip Hampton is set to become GlaxoSmithKline's (GSK) chairman as early as this summer. Reference Link
11:17 EDTGSKFTC puts conditions on Novartis's proposed acquisition of GSK oncology drugs
According to the FTC, Global pharmaceutical company Novartis (NVS) has agreed to divest all assets related to its BRAF and MEK inhibitor drugs, currently in development, to Boulder, Colorado-based Array BioPharma (ARRY) to settle charges that Novartis’s $16B acquisition of GlaxoSmithKline’s (GSK) portfolio of cancer-treatment drugs would likely be anticompetitive...If the acquisition goes forward as proposed, Novartis would likely delay or terminate development of both its BRAF and MEK inhibitors, as well as the combination product. For that reason, Novartis’s acquisition of GSK’s portfolio of cancer-treatment drugs would likely cause significant competitive harm in the U.S. markets for both the BRAF and MEK inhibitors, ultimately raising prices for consumers and depriving them of potentially superior products. Under the terms of the proposed consent agreement, Novartis is required to provide transitional services to Array BioPharma to ensure that development of the BRAF and MEK inhibitors continues uninterrupted and that competition in BRAF and MEK inhibitor markets is not reduced. Reference Link
February 22, 2015
21:52 EDTABCVascular Solutions to replace MWI Veterinary Supply in S&P 600 as of 2/23 close
S&P 500 constituent AmerisourceBergen (ABC) is acquiring MWI Veterinary Supply (MWIV) in a transaction expected to be completed soon.
12:51 EDTCAHJ&J considers Cordis sale with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
February 20, 2015
17:31 EDTCAHJ&J considering sale of Cordis with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
07:23 EDTGSKAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTGSKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
08:23 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
Subscribe for More Information
February 17, 2015
07:38 EDTGSKGlaxo replaces head of struggling U.S. drug unit, Bloomberg reports
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use